feed,title,long_url,short_url
Benzinga,DupixentÂ® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children's lung function in a randomized Phase 3 trial,https://www.benzinga.com/pressreleases/20/10/g17876988/dupixent-dupilumab-significantly-reduced-severe-asthma-attacks-in-children-and-is-the-only-biologi,https://j.mp/3lFC4A9
